Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sysmex ( (JP:6869) ) has issued an announcement.
Sysmex reported a 1.6% decline in net sales to ¥361.2 billion for the nine months ended December 31, 2025, with operating profit down 27.7% and profit attributable to owners of the parent falling 20.9%. Despite weaker earnings and lower basic earnings per share, total assets and equity attributable to owners increased, lifting the equity ratio to 71.7% and underscoring a solid balance sheet.
The company maintained its dividend policy and plans an annual ¥38 per share payout for the year ending March 31, 2026, including commemorative dividends for the 30th anniversary of its listing. Sysmex also cut its full-year forecast, now expecting a 1.7% decline in net sales and a roughly 29% drop in operating profit, signaling a more challenging earnings environment but continued shareholder returns through stable dividends.
The most recent analyst rating on (JP:6869) stock is a Buy with a Yen1642.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.
More about Sysmex
Sysmex Corporation is a Japan-based healthcare company specializing in in-vitro diagnostics, including hematology and clinical laboratory testing systems. Listed on the Tokyo Stock Exchange, the company focuses on global markets for diagnostic equipment and reagents used in hospitals and laboratories, generating recurring revenue from installed testing platforms and related services.
Average Trading Volume: 3,354,568
Technical Sentiment Signal: Sell
Current Market Cap: Yen948.2B
For an in-depth examination of 6869 stock, go to TipRanks’ Overview page.